Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter Ling

Showing results (71-80 of 164) with videos related to

Pageof 17
Sort By:
Journal of Addiction Medicine|September 16, 2022
Continued Posttrial Benefits of Buprenorphine Extended Release: RECOVER Study FindingsBrent Boyett, Vijay R Nadipelli, Caitlyn T Solem, et al.
Lancet (London, England)|August 23, 2011
Injectable extended-release naltrexone for opioid dependenceEvgeny Krupitsky, Edward V Nunes, Walter Ling, et al.
Addiction (Abingdon, England)|May 25, 2013
Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectivenessEvgeny Krupitsky, Edward V Nunes, Walter Ling, et al.
Journal of Addictive Diseases|February 8, 2002
Cognitive performance of current methamphetamine and cocaine abusersSara L Simon, Catherine P Domier, Tiffanie Sim, et al.
Journal of Addictive Diseases|February 8, 2002
Cognitive deficits among methamphetamine users with attention deficit hyperactivity disorder symptomatologyTiffanie Sim, Sara L Simon, Catherine P Domier, et al.
Pain|January 24, 2006
Methadone maintenance patients are cross-tolerant to the antinociceptive effects of very high plasma morphine concentrationsPeter Athanasos, Charlotte S Smith, Jason M White, et al.
Pharmacology, Biochemistry, and Behavior|September 27, 2005
Apathy predicts hedonic but not craving response to cocaineThomas F Newton, Ari D Kalechstein, Richard De La Garza, et al.
Journal of Addictive Diseases|February 8, 2002
Status of methamphetamine users 2-5 years after outpatient treatmentRichard A Rawson, Alice Huber, Paul Brethen, et al.
The American Journal of Drug and Alcohol Abuse|April 20, 2018
Sex differences in opioid use and medical issues during buprenorphine/naloxone treatmentCelestina Barbosa-Leiker, Sterling McPherson, Matthew E Layton, et al.
Lancet (London, England)|May 3, 2011
Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trialEvgeny Krupitsky, Edward V Nunes, Walter Ling, et al.
Pageof 17

Showing results (71-80 of 164) with videos related to

Sort By:
Pageof 17
Journal of Addiction Medicine|September 16, 2022
Continued Posttrial Benefits of Buprenorphine Extended Release: RECOVER Study FindingsBrent Boyett, Vijay R Nadipelli, Caitlyn T Solem, et al.
Lancet (London, England)|August 23, 2011
Injectable extended-release naltrexone for opioid dependenceEvgeny Krupitsky, Edward V Nunes, Walter Ling, et al.
Addiction (Abingdon, England)|May 25, 2013
Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectivenessEvgeny Krupitsky, Edward V Nunes, Walter Ling, et al.
Journal of Addictive Diseases|February 8, 2002
Cognitive performance of current methamphetamine and cocaine abusersSara L Simon, Catherine P Domier, Tiffanie Sim, et al.
Journal of Addictive Diseases|February 8, 2002
Cognitive deficits among methamphetamine users with attention deficit hyperactivity disorder symptomatologyTiffanie Sim, Sara L Simon, Catherine P Domier, et al.
Pain|January 24, 2006
Methadone maintenance patients are cross-tolerant to the antinociceptive effects of very high plasma morphine concentrationsPeter Athanasos, Charlotte S Smith, Jason M White, et al.
Pharmacology, Biochemistry, and Behavior|September 27, 2005
Apathy predicts hedonic but not craving response to cocaineThomas F Newton, Ari D Kalechstein, Richard De La Garza, et al.
Journal of Addictive Diseases|February 8, 2002
Status of methamphetamine users 2-5 years after outpatient treatmentRichard A Rawson, Alice Huber, Paul Brethen, et al.
The American Journal of Drug and Alcohol Abuse|April 20, 2018
Sex differences in opioid use and medical issues during buprenorphine/naloxone treatmentCelestina Barbosa-Leiker, Sterling McPherson, Matthew E Layton, et al.
Lancet (London, England)|May 3, 2011
Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trialEvgeny Krupitsky, Edward V Nunes, Walter Ling, et al.
Pageof 17